XML 19 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues    
Total revenues $ 2,392 $ 709
Cost of revenues 508 488
Gross profit 1,884 221
Operating expenses    
General and administrative 10,269 12,184
Research and development 8,137 9,066
Total operating expenses 18,406 21,250
Loss from operations (16,522) (21,029)
Other income and (expense)    
Lawsuit expense   (30)
Other refundable tax credits   23
Other income (expense), net 549 (377)
Total other income (expenses), net 549 (384)
Net loss (15,973) (21,413)
Deemed dividend - warrant inducement offers (8,650) (798)
Net loss attributable to common stockholders $ (24,623) $ (22,211)
Basic net loss per share $ (2.62) $ (10.22)
Diluted net loss per share $ (2.62) $ (10.22)
Basic weighted average common shares outstanding 9,411,164 2,173,490
Diluted weighted average common shares outstanding 9,411,164 2,173,490
Clinical trial revenue    
Revenues    
Total revenues $ 1,402 $ 668
Contract manufacturing lease revenue    
Revenues    
Total revenues 503
Contract manufacturing revenue    
Revenues    
Total revenues $ 487
Grant revenue    
Revenues    
Total revenues   $ 41